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Background: M3 muscarinic acetylcholine receptor (M3-mAChR) is stably expressed in the myocardium, but its
pathophysiological role remains largely undefined. This study aimed to investigate the role of M3-mAChR in cardiac
hypertrophy induced by angiotensin II (Ang II) and elucidate the underlying mechanisms.
Methods: Cardiac-specific M3-mAChR overexpression transgenic (TG) mice and rat H9c2 cardiomyoblasts with ectopic
expression of M3-mAChR were established. Models of cardiac hypertrophy were induced by transverse aortic constriction
(TAC) or Ang II infusion in the mice in vivo, and by isoproterenol (ISO) or Ang II treatment of H9c2 cells in vitro. Cardiac
hypertrophy was evaluated by electrocardiography (ECG) measurement, hemodynamic measurement and histological
analysis. mRNA and protein expression were detected by real-time RT-PCR and Western blot analysis.
Results: M3-mAChR was upregulated in hypertrophic heart, while M2-mAChR expression did not change significantly.
M3-mAChR overexpression significantly attenuated the increased expression of atrial natriuretic peptide and β-myosin
heavy chain induced by Ang II both in vivo and in vitro. In addition, M3-mAChR overexpression downregulated AT1
receptor expression and inhibited the activation of MAPK signaling in the heart.
Conclusion: The upregulation of M3-mAChR during myocardial hypertrophy could relieve the hypertrophic response
provoked by Ang II, and the mechanism may involve the inhibition of MAPK signaling through the downregulation of
AT1 receptor.
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Heart failure is a significant cause of mortality and morbid-
ity [1,2]. Cardiac hypertrophy is a common precursor to
many forms of heart failure. Despite recent advances in the
understanding of the pathogenesis of cardiac hypertrophy,
currently available medications could not effectively reverse
pathologic cardiac hypertrophy. Therefore, the identifica-
tion of novel therapeutic targets for cardiac hypertrophy is
pivotal for the development of effective treatment strat-
egies. Sympathetic and parasympathetic divisions of the
autonomic nervous systems play a major role in the regula-
tion of cardiac function. Thus, increased attention has been* Correspondence: yjlu86@gmail.com; dzm1956@126.com
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reproduction in any medium, provided the orpaid to the changes in the cardiac autonomic innervation
in cardiac hypertrophy and failure [3-5].
Previous studies have shown that the M3 muscarinic
acetylcholine receptor (M3-mAChR) is expressed in the
hearts of various species, including human, canine, guinea-
pig and rabbit [6-8]. M3-mAChR plays important role in
the regulation and maintenance of cardiac function and
heart disease [9-11]. The cardiac M3-mAChR has demon-
strated negative chronotropic and inotropic effects [12].
Heart rate (HR) correlates with myocardial oxygen con-
sumption and coronary blood flow in normal and patho-
logic hearts. High HR is an independent predictor of
total and cardiovascular mortality in patients with coronary
artery disease and left ventricular systolic dysfunction
[13,14]. Furthermore, Lamping et al. demonstrated that
endothelium-dependent relaxation to acetylcholine in cor-
onary circulation was mediated predominantly by the acti-
vation of M3-mAChR [15].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mAChR and M3-mAChR were associated with atrial
dilation [16]. However, the involvement of M3-mAChR
in ventricular hypertrophy remains largely unexplored.
Therefore, we hypothesized that cardiac M3-mAChR has
potential effects on cardiac hypertrophy, in addition to im-
proving coronary circulation and reducing HR. To test our
hypothesis, we generated cardiac-specific overexpression
M3-mAChR transgenic (TG) mice and rat H9c2 cell line
that overexpressed M3-mAChR (TG-H9c2). Using these
models, we demonstrated that the upregulation of M3-
mAChR inhibited cardiac hypertrophy induced by angio-
tensin II (Ang II).
Materials and methods
Animals
The animals were kept under standard animal room condi-
tions (temperature 21 ± 1°C; humidity 55 ± 5%) with food
and water unlimited. All experimental protocols were ap-
proved by the Experimental Animal Ethic Committee of
Harbin Medical University, China. Use of animals followed
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996).
Construction of M3-mAChR overexpression TG mice model
TG mice were generated by using a construct in which
the α-myosin heavy chain (α-MHC) promoter drove the
exclusive expression of M3-mAChR in cardiomyocytes
[17]. TG mice and their wild-type (WT) littermates of
either sex, 8–12 weeks old, with a body weight of 20–
25 g, were used. Age-matched WT and TG mice were
randomly divided into 4 groups: (1) vehicle-infused WT
mice (WT-CTRL); (2) Ang II-infused WT mice (WT-
Ang II); (3) vehicle-infused TG mice (TG-CTRL); (4) Ang
II-infused TG mice (TG-Ang II). Ang II (0.6 mg/kg
per day) or normal saline (NS) was injected subcutaneously
for 14 days as described previously [18].
Echocardiographic analysis
Mice were anesthetized by intraperitoneal injection of
sodium pentobarbital (65 mg/kg) (Sigma, St Louis, MO,
USA). Then, transthoracic echocardiography was per-
formed with an echocardiographic system equipped
with a 10.0-MHz phase-array transducer (GE Vivid 7,
GE, USA). Left ventricular diameter and wall thickness
were measured using M-mode tracings as described
previously [19].
Hemodynamic measurements, heart weight (HW)
measurement and histological analysis
After treatment with Ang II, mice were anaesthetized
by intraperitoneal injection of sodium pentobarbital
(65 mg/kg), and then put on a heated platform for bodytemperature and electrocardiography (ECG) measure-
ments. Pressure-volume control unit FV896B PV catheter
(Scisense advancing micro-sensor technology, London,
Ontario, Canada) was inserted through the right carotid
artery into the aorta for mean arterial blood pressure
(MAP) measurement [18]. Next, the hearts were quickly
excised and washed with cold (4°C) PBS buffer. The ratio
of whole heart weight to body weight (HW/BW) and left
ventricular weight to body weight (LVW/BW) was mea-
sured. Ventricle tissue was then equally divided into three
parts. One part was fixed with 4% paraformaldehyde and
then stained with hematoxylin and eosin (HE). The other
two parts and atrium tissues were frozen in liquid nitrogen
and stored at −80°C for subsequent analysis.
Transverse aortic constriction
The pressure-overload cardiac hypertrophy model was
induced by transverse aortic constriction (TAC) as de-
scribed previously [20]. Adult mice (BDF1, 24 ± 2 g),
were anesthetized by intraperitoneal injection of sodium
pentobarbital (65 mg/kg). After successful endotracheal
intubation, the cannula was connected to a volume cy-
cled rodent ventilator (UGO BASILE S.R.L. Italy).The
transverse aorta was isolated from annexed tissue, and
the artery was partially ligated immediately with 7–0 silk
around a 25-gauge blunted needle, which was subse-
quently removed. Sham operated mice underwent the
same procedure, except that the transverse aorta was not
partially ligated. The chest was closed and the animals
were kept ventilated until the recovery of autonomic
breath, and then raised for 14 days.
Preparation of neonatal rat ventricular myocytes (NRVMs)
NRVMs were isolated from 1-day-old neonatal Wistar
rat hearts and differentially plated to remove fibroblasts
[21]. Ang II (Sigma, St Louis, MO, USA) or isoproterenol
(ISO) (Sigma, St Louis, MO, USA) was added to the cul-
ture medium at a final concentration of 0.1 μM or 10 μM
for 48 h to induce hypertrophy [18,22]. The cells were then
harvested to determine M3-mAChR expression during car-
diac hypertrophy.
Construction of M3-mAChR overexpression TG-H9c2
cell model
pcDNA3.1 (+) human M3-mAChR vector was constructed
and transfected into rat H9c2 cardiomyoblasts plated on
BioFlex plates. After 48 h, cells were cultured in DMEM
supplemented with 10% (v/v) heat-inactivated FBS and
500 μg/mL G418 at 37°C in 5% CO2 and 95% air, at a rela-
tive humidity of 95%. The cells were split 1 to 3 at sub-
confluence (70%). Before each experiment, cells were
seeded at a density of 5 × 104 cells/cm2. H9c2 cells were
cultured in serum-free DMEM for 12 h before treatment
with or without 0.1 μM Ang II for 48 h. To quantify the
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orange. The relative surface area of the cells was cal-
culated from the number of pixels by using Image-Pro Plus
(version 5.0.1).
Western blot analysis
Total proteins (~60 μg) were extracted from cells or tis-
sues as described previously [23], fractionated by 10%
SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose membrane. The membrane was incubated at
4°C overnight with the primary antibodies against M3-
mAChR, M2-mAChR (Alomone Labs, Jerusalem, Israel);
Ang II type 1 receptor (AT1 R) (Sigma, St Louis, MO,
USA); c-Jun N-terminal kinases (JNK), phospho-JNK
(p-JNK), extracellular regulated protein kinase (ERK),
phospho-ERK (p-ERK) and p38 mitogen-activated pro-
tein kinase (MAPK) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), phospho-p38 (p-p38) (Cell SignalingFigure 1 Upregulation of M3-mAChR expression in in vitro and in vivo
and M2-mAChR protein levels in ventricular tissues from mice with chronic
mice per group); (c) Western blot analysis of M3-mAChR protein level in ne
for 48 hours (n = 3); (d, e) Western blot analysis of M3-mAChR and M2-mAC
overload by transverse aotic constriction (TAC) for 14 days (n = 4 mice per
isoproterenol (ISO) (10 μM) for 48 hours (n = 3). GAPDH served as loading c
CTRL group. *P < 0.05 vs. CTRL group.Technology, Boston, USA), followed by incubation with
the secondary antibody Alexa Fluor 800 rabbit anti-
mouse IgG (H + L) or Alexa Fluor 800 goat anti-rabbit
IgG (H + L) (Invitrogen, Carlsbad, USA). The images were
captured on the Odyssey Infrared Imaging System (LI-
COR, Upland, CA, USA) and band intensity (area ×OD)
was quantified using Odyssey v1.2 software with GAPDH
as loading control.
Real-time quantitative RT-PCR analysis
Total RNA was extracted from the tissues using Trizol
reagent (Invitrogen, USA). First-strand cDNA was syn-
thesized by a reverse transcriptase kit (Invitrogen, USA)
according to the manufacturer’s instructions, and used as
the template for Quatitative RT-PCR analysis on a ABI
7500 fast Real Time system (Applied Biosystems, Foster
City, CA, USA), with GAPDH used as an internal con-
trol [15]. The primer sequences were as follows: GAPDH,models of hypertrophy. (a, b) Western blot analysis of M3-mAChR
angiotensin II (Ang II) (0.6 mg/kg per day) infusion for 14 days (n = 4
onatal rat ventricular myocytes (NRVMs) incubated with Ang II (0.1 μM)
hR protein levels in ventricular tissues from mice with pressure
group); (f) M3-mAChR protein level from NRVMs incubated with
ontrol. Values were expressed as mean ± SEM and normalized to the
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TCCACCACCCTGTTGCTGTA-3′ (reverse); β-myosin
heavy chain (β-MHC), 5′-CCAGAAGCCTCGAAATG
TC-3′ (forward), 5′-CTTTCTTTGCCTTGCCTTTGC-3′
(reverse); Atrial natriuretic peptide (ANP), 5′-CTCCGAT
AGATCTGCCCTCTTGAA-3′ (forward), 5′-GGTACCG
GAAGCTGTTGCAGCCTA-3′ (reverse); M3-mAChR, 5'-
CATCATCGGCAACATCCT-3' (forward) and 5'-GAGGT
CACAGGCTAAGTTC-3' (reverse).
Statistical analysis
Data were expressed as means ± SEM and analyzed with
SPSS 13.0 software. Comparisons between two groups
were made using Student’s t-test. Comparisons among
multiple groups were performed using analysis of vari-
ance (ANOVA) followed by Bonferroni post test. Differ-
ences were considered to be significant at P < 0.05.
Results
Hypertrophic stimulation increases M3-mAChR expression
in vivo and in vitro
To assess the pathophysiological role of M3-mAChR in
the heart, we first measured the M3-mAChR expression
level in the ventricle during cardiac hypertrophy in vivo.
We observed a 1.69 ± 0.18 fold increase and a 1.33 ± 0.14
fold increase in M3-mAChR protein level in the heartsFigure 2 The effects of M3-mAChR overexpression on Ang II-induced
mRNA expression levels were increased in TG-H9c2 cells. TG-H9c2 cell, H9c
type H9c2 cell line. Values were expressed as means ± SEM (n = 3) and normali
overexpression inhibited the increase of cell surface area induced by angiotens
and β-myosin heavy chain (β-MHC) in TG-H9c2 cells. Values were expressed as
WT-CTRL group; #P< 0.05 vs. WT-Ang II group.of mice after Ang II infusion or chronic pressure over-
load via TAC for 14 days, respectively, compared with the
control (CTRL) group (Figure 1a and d). However, M2-
mAChR protein level remained unchanged in both treat-
ment groups (Figure 1b and e). Furthermore, M3-mAChR
protein level was upregulated after Ang II or isoproterenol
(ISO) treatment for 48 h in NRVMs compared with CTRL
(Ang II 1.40 ± 0.04; ISO 1.36 ± 0.03) (Figure 1c and f). Be-
sides, RT-PCR analysis confirmed that Chrm3 gene expres-
sion was also upregulated in hypertrophic cardiomyocytes
(Additional file 1: Figure S1). Taken together, these data
suggest that M3-mAChR expression is upregulated by
hypertrophy both in vivo and in vitro.
M3-mAChR overexpression exhibits anti-hypertrophic
effects in H9c2 cells
To explore the biological significance of M3-mAChR
expression upregulation in the heart, we compared
TG-H9c2 cells with WT-H9c2 cells (Figure 2a and b). The
cell surface area was significantly increased after Ang
II infusion in WT-H9c2 cells compared with TG-
H9c2 cells (WT-Ang II 1.09 ± 0.03 vs. TG-Ang II
0.95 ± 0.04) (Figure 2c). In addition, the mRNA expres-
sion levels of ANP and β-MHC, which are cardiac
hypertrophy-related genes, were increased by 25.76 ±
6.65 and 4.53 ± 0.43 fold, respectively, after the incubationcardiac hypertrophy in H9c2 cells. (a, b) M3-mAChR protein and
2 cell line with ectopic expression of M3-mAChR; WT-H9c2 cell, wide
zed to the WT-H9c2 group. *P <0.05 vs. WT-H9c2 group. (c) M3-mAChR
in II (Ang II). (d, e) The mRNA expression of atrial natriuretic peptide (ANP)
means ± SEM (n = 3) and normalized to the WT-CTRL group, *P <0.05 vs.
Table 1 Bodyweight (BW), heart rate (HR), mean arterial pressure (MAP), ejection fraction (EF) and echocardiographic
measurements after Ang II infusion in the mice
Variable WT-CTRL (n = 6) WT-Ang II (n = 6) TG-CTRL (n = 6) TG-Ang II (n = 6)
BW, g 23.18 ± 1.68 20.93 ± 1.54 23.50 ± 1.15 21.30 ± 1.05
HR, bpm 471.74 ± 37.90 642.26 ± 45.85* 470.07 ± 34.77 539.20 ± 54.83#
MAP, mmHg 91.54 ± 3.94 106.57 ± 5.29* 99.44 ± 4.02 88.71 ± 3.72#
Echocardiography(n = 5)
IVSd, mm 0.96 ± 0.05 1.26 ± 0.07* 0.86 ± 0.05 1.02 ± 0.06#
IVSs, mm 1.38 ± 0.06 1.70 ± 0.04* 1.36 ± 0.07 1.42 ± 0.09#
LVPWd, mm 0.94 ± 0.02 1.16 ± 0.07* 0.94 ± 0.05 0.90 ± 0.04#
LVPWs, mm 1.30 ± 0.07 1.44 ± 0.08 1.24 ± 0.04 1.12 ± 0.08#
LVDd, cm 3.24 ± 0.32 3.24 ± 0.16 3.02 ± 0.20 3.00 ± 0.12
LVDs, cm 2.00 ± 0.05 1.84 ± 0.04 1.68 ± 0.04 1.72 ± 0.06
EF 0.75 ± 0.02 0.80 ± 0.04 0.81 ± 0.02 0.77 ± 0.08
IVSd diastolic intraventricular septum thickness, IVSs systolic intraventricular septum thickness, LVPWd diastolic left ventricular posterior wall thickness, LVPWs
systolic left ventricular posterior wall thickness, LVDd diastolic systolic left ventricular diameter, LVDs systolic left ventricular diameter, EF ejection fraction. Values
were expressed as means ± SEM (n = 6), *P < 0.05 vs. WT-CTRL group; #P < 0.05 vs. WT-Ang II group. WT-CTRL, vehicle-infused wild type (WT) mice; WT-Ang II,
angiotensin II (Ang II)-infused WT mice; TG-CTRL, vehicle-infused transgenic (TG) mice; TG-Ang II, Ang II-infused TG mice.
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(Figure 2d and e).
M3-mAChR overexpression attenuates cardiac hypertrophy
induced by chronic Ang II infusion in mice
To further demonstrate the anti-hypertrophic effects of
cardiac M3-mAChR in vivo, TG mice were generated
with cardiac-specific overexpression of M3-mAChR. AsFigure 3 The effects of M3-mAChR overexpression on Ang II-induced car
(a) Representative hearts from WT and M3-mAChR overexpression transgenic (T
for 14 days. (b, c) The ratio of heart weight (HW) and left ventricle weight (LVW
representative hearts. (e, f) The mRNA expression of atrial natriuretic peptide (AN
SEM (n = 6) and normalized to the WT-CTRL group, *P< 0.05 vs. WT-CTRL group
vehicle-infused wild type (WT) mice; WT-Ang II, Ang II-infused WT mice; TG-CTRexpected, Ang II infusion induced significant increases in
the diastolic intraventricular septum (IVSd), systolic in-
traventricular septum (IVSs) and diastolic left ventricular
posterior wall (LVPWd) thickness of the hearts estimated
by echocardiography in WT mice. Meanwhile, HW/BW
and LVW/BW ratio, heart rate, and mean arterial pressure
(MAP) were also increased (Table 1, Figure 3b and c).
However, the cardiac hypertrophic responses to Ang IIdiac hypertrophy in cardiac-specific M3-mAChR overexpression mice.
G) mice treated with vehicle or angiotensin II (Ang II) (0.6 mg/kg per day)
) to body weight (BW). (d) Hematoxylin-Eosin (HE) stained sections of
P) and β-myosin heavy chain (β-MHC). Values were expressed as means ±
; **P< 0.01 vs. WT-CTRL group; #P< 0.05 vs. WT-Ang II group. WT-CTRL,
L, vehicle-infused transgenic (TG) mice; TG-Ang II, Ang II-infused TG mice.
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and c). HE staining showed that M3-mAChR over-
expression inhibited Ang II induced cardiomyocyte cross
sectional area increase (Figure 3d, Additional file 2:
Figure S2). Furthermore, real time RT-PCR analysis
showed that the mRNA levels of ANP and β-MHC were
increased after Ang II infusion in WT mice compared to
those in TG mice (ANP, WT-Ang II 2.17 ± 0.58 vs. TG-
Ang II 0.99 ± 0.24; β-MHC, WT- Ang II 2.42 ± 0.59 vs.
TG- Ang II 0.36 ± 0.16) (Figure 3e and f). These results
indicate that the cardiac hypertrophic effects induced by
Ang II infusion were suppressed in TG mice with cardiac-
specific overexpression of M3-mAChR.
M3-mAChR downregulates AT1 R expression
and the activation of MAPK signaling in TG mice
To determine the role of AT1 R in the anti-hypertrophic ef-
fects mediated by M3-mAChR upregulation, we measured
AT1 R protein expression level in mice. Western blot ana-
lysis showed that Ang II induced the upregulation of AT1Figure 4 The changes of AT1 R, p-ERK1/2, p- p38-MAPK, and p-JNK level
analysis of angiotensin II type 1 receptor (AT1 R) protein level in WT and TG mi
increased phospho-extracellular regulated protein kinase (p-ERK) (b), phospho-
(d) induced by angiotensin II (Ang II) infusion were attenuated in TG mice. Pho
levels were relative to GAPDH. GAPDH served as loading control. Values were e
Values were expressed as means ± SEM. *P < 0.05 vs. WT-CTRL group; #P< 0
WT-Ang II, Ang II -infused WT mice; TG-CTRL, vehicle-infused transgenic (TGR protein expression compared with CTRL in WT mice
(Figure 4a). However, Ang II failed to induce the
upregulation of AT1 R protein expression in TG mice with
overexpression of M3-mAChR. As the downstream effector
of AT1 R signaling pathway, MAPK plays an important role
in the development of cardiac hypertrophy [24-26]. To fur-
ther explore the underlying molecular mechanism, the
basal and activated levels of JNK, ERK and p38 MAPK
were examined in transgenic hypertrophic mice. The levels
of p-JNK, p-ERK and p-p38 MAPK were increased in WT
mice after Ang II treatment (Figure 4b to d), indicating the
activation of MAPK signaling. However, Ang II induced
activation of MAPK signaling was abolished in TG mice
because the levels of p-JNK, p-ERK and p-p38 MAPK were
not significantly increased in these mice.
Discussion
In the present study we reported several interesting
findings: (1) M3-mAChR is upregulated during Ang II-
induced cardiac hypertrophy both in vivo and in vitro;s in cardiac-specific M3-mAChR overexpression mice. (a) Western blot
ce treated with vehicle or Ang II (0.6 mg/kg per day) for 14 days. The
p-p38 (p-p38) level (c) and phospho- c-Jun N-terminal kinases (p-JNK) level
spho-protein levels were relative to total protein levels, while total protein
xpressed as mean ± SEM (n = 6) and normalized to the CTRL group.
.05 vs. WT-Ang II group. WT-CTRL, vehicle-infused wild type (WT) mice;
) mice; TG-Ang II, Ang II-infused TG mice.
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hypertrophy induced by chronic Ang II infusion; (3) Up-
regulation of M3-mAChR is mediated by decreased phos-
phorylation of ERK, JNK, and p38 MAPK cascades
through the downregulation of AT1 R. These results pro-
vide novel insight into the mechanisms underlying the
cardioprotective effects of M3-mAChR in cardiac hyper-
trophy, and indicate that M3-mAChR is a potential thera-
peutic target.
Previous studies have demonstrated that the expres-
sion of M3-mAChR is upregulated during ventricular
myocardial ischemia and atrial fibrillation [10,11,27].
Similarly, in the present study, we found that the protein
level of M3-mAChR was upregulated during cardiac hyper-
trophy both in vivo and in vitro. As a control, we detected
M2-mAChR protein expression and found no significant
change in hypertrophic heart. These data indicate the spe-
cific role of M3-mAChR in cardiac hypertrophy.
The activation of AT1 R through the renin-angiotensin
system (RAS) plays an important role in the development
of cardiac hypertrophy [28,29]. Ang II not only regulates
the vasculature, but also promotes the growth of cardiac
tissues, resulting in myocardial hypertrophy independently
of hypertension [26]. The antagonist of AT1 R is widely
used for the treatment of hypertension, and is an import-
ant drug for the prevention of cardiac remodeling after
myocardial infarction. Ang II activates several intracellular
signaling pathways such as MAPK signaling [25]. The p38
MAPK cascade has been shown to play a critical role in
the pathogenesis of cardiac hypertrophy [25,26,29]. Liu
et al. have demonstrated that acetylcholine prevented Ang
II-induced apoptosis of H9c2 cells via the downregulation
of AT1 R, the inhibition of ROS-mediated p38 MAPK acti-
vation, as well as the regulation of Bcl-2, Bax and caspase-
3 [24]. In addition, previous study showed that M3-mAChR
was closely related to ERK and p38 MAPK [30]. In the
present study we found that the phosphorylation levels of
ERK1/2, JNK and p38 were increased in response to hyper-
trophic stimulation in WT mice but not in TG mice, con-
sistent with previous studies that the p38 MAPK and
ERK1/2 were involved in cardiac hypertrophy [2]. Taken
together, these data suggest that MAPK signaling is cru-
cially involved in the regulation of cardiac myocytes by
M3-mAChR. Suppression of the MAPK signaling by M3-
mAChR through the downregulation of AT1 R in the heart
may attenuate cardiac remodeling.
It is worth mentioning that the physiological parameters,
such as BW, HR, cardiac functions, and HW/BW and
LVW/BW ratio, are comparable at baseline in WT and TG
mice, thus the effects of cardiac-specific overexpression of
M3-mAChR are likely to be exerted only in the context of
hypertrophy stimulation.
In summary, the current study provides new insight into
the role of M3-mAChR upregulation in the development ofcardiac hypertrophy induced by Ang II. Our findings sug-
gest that M3-mAChR functions as an endogenous negative
regulator of hypertrophic response, thus representing a
novel therapeutic target for cardiac hypertrophy. Add-
itional studies to elucidate the molecular mechanisms of
the anti-hypertrophic properties of cardiac M3-mAChR
will promote the application of M3-mAChR regulators in
the clinic.
Additional files
Additional file 1: Figure S1. Upregulation of M3-mAChR mRNA
expression in in vitro and in vivo models of hypertrophy. (a) M3-mAChR
mRNA levels in ventricular tissues from mice with chronic angiotensin II
(Ang II) (0.6 mg/kg per day) infusion for 14 days (n = 4 mice per group);
(b) M3-mAChR mRNA level from neonatal rat ventricular myocytes
(NRVMs) incubated with isoproterenol (ISO) (10 μM) for 48 hours (n = 4).
Values were expressed as mean ± SEM and normalized to the CTRL
group. *P < 0.05 vs. CTRL group.
Additional file 2: Figure S2. M3-mAChR overexpressioninhibited
angiotensin II (Ang II) induced cardiomyocyte cross-sectional area
increase. Values were expressed as means ± SEM and normalized to the
WT-CTRL group, *P < 0.05 vs. WT-CTRL group. #P < 0.05 vs. WT-Ang II group.
WT-CTRL, vehicle-infused wild type (WT) mice; WT-Ang II, Ang II-infused WT
mice; TG-CTRL, vehicle-infused transgenic (TG) mice; TG-Ang II, Ang II-infused
TG mice.
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